Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow

    Krishna Dani, Lesley Murray, Anissa Benchiheub, George Gorrie, Johann Selvarajah, Sandeep Sharma, Michael McKenzie, Laura McCorkell, Christine Rankin, Alok Tyagi
    New to Botox? There is a guide in the encyclopedia. Read the guide →
    Studysummary In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →